EFFECT OF PROBIOTIC LACTOBACILLUS FERMENTUM MCC3216 ON PROGRESSION OF TYPE 2 DIABETES WITH THEIR ANTI-INFLAMMATORY ACTIVITY IN HIGH FRUCTOSE FED DIABETIC RATS

The antidiabetic and anti-inflammatory effects of probiotic Lactobacillus fermentum MCC3216 was investigated in high fructose-fed type 2 diabetic rats. Type 2 diabetes was induced by feeding high fructose diet to male albino Wistar rats. A single daily dose of 2 × 10⁸ CFU/ml of L. fermentum MCC3216 was given to Wistar rats for 8 weeks. The fasting blood glucose, body weight, oral glucose tolerance test, glycosylated hemoglobin, insulin, liver glycogen, lipid profile, and oxidative stress parameters were measured. The level of Interleukin-6 and Interleukin-10 were also measured in serum. Histopathology analysis of pancreas and liver injury were performed. At 8 week L. fermentum MCC3216 significantly (P<0.05) decrease FBG, body weight, glucose intolerance, HbA1c, insulin, liver glycogen, total cholesterol, triacylglycerol, LDL-C, VLDL-C, lipid peroxidation and IL-6 level as compared to diabetic rats. The values for HDL-C, reduced glutathione, superoxide dismutase, catalase and IL-10 were significantly (P<0.05) increased in L. fermentum MCC3216 treated group as compared to diabetic rats. Islets of Langerhans and hepatic cells in L. fermentum MCC3216 treated group were protected from destruction as compared to the diabetic rats. L. fermentum MCC3216 exerts the antidiabetic and anti-inflammatory effect on high fructose-fed type 2 diabetic rats and significantly improves hyperglycemia, hyperinsulinemia, glucose intolerance, dyslipidemia, oxidative stress and regulates immunological responses. These results suggest that further research is required in other diabetic models for clinical application of L. fermentum MCC3216 in progression and delay of T2DM.